CRA consultants assessed whether disputed representations of bioequivalence significantly affected sales of the branded product. The evaluation included consideration of distribution channels, purchase timing, and the effect of payor control mechanisms on product uptake and sales. The case ultimately resulted in a settlement.
A tale of two stakeholder groups in regulating healthcare AI
Despite significant spending on healthcare in the US, the industry is slow to adopt AI technology that can cut costs and improve efficiency. In this CPI...